查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胰岛素市场2028年前的预测-COVID-19影响与各类型·各地区的全球分析
市场调查报告书
商品编码
1118302

胰岛素市场2028年前的预测-COVID-19影响与各类型·各地区的全球分析

Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography
出版日期: | 出版商: The Insight Partners | 英文 255 Pages | 订单完成后即时交付

价格

胰岛素市场在2021年估算为546亿1142万美元，到2028年达到1112亿1373万美元。市场在2022年～2028年间，预测将以年复合成长率是以10.8％成长。

本报告提供全球胰岛素市场相关调查，提供市场概要，以及各各类型·各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 简介

  • 调查目标范围
  • Insight Partners的调查报告书指导
  • 市场区隔
    • 胰岛素的全球市场-各类型
    • 胰岛素的全球市场-各地区

第2章 胰岛素的全球市场-主要的要点

第3章 调查手法

  • 调查对象
  • 2次调查
  • 1次调查

第4章 胰岛素市场- 市场形势

  • PEST分析
    • 北美-PEST分析
    • 欧洲-PEST分析
    • 亚太地区-PEST分析
    • 中东·非洲地区PEST分析
    • 中南美PEST分析
    • 专家的见解

第5章 胰岛素市场-主要的市场动态

  • 推动市场要素
  • 阻碍市场要素
  • 市场机会
  • 今后趋势
  • 促进因素和阻碍因素的影响分析

第6章 胰岛素市场-世界分析

  • 胰岛素的全球市场收益和预测及分析
    • 胰岛素的全球市场，各地区预测及分析
    • 胰岛素的全球市场-市场潜在力分析，各地区
  • 企业分析
    • 主要企业的市场定位
    • 企业比较分析
    • 成长策略分析
    • 主要企业的业绩
      • 诺和诺德A/S
      • Sanofi
      • Elilily·与·公司
  • 客制化部分
    • 各企业市场占有率分析
    • 各注射剂GLP市场占有率分析

第7章 胰岛素市场分析-各类型

  • 胰岛素各市场类型销售额占有率(2021年，2028年)
  • 长效型胰岛素
  • 速效型胰岛素
  • 短效型胰岛素和传统的人类胰岛素
  • 浓缩胰岛素和配合胰岛素
  • 生物相似药胰岛素
  • Glucagon-Like Peptide-1(GLP-1)
  • 笔·针头
  • 其他

第8章 胰岛素的全球市场- 各地区分析

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 中东·非洲地区
    • UAE
    • 沙乌地阿拉伯
    • 南非
    • 其他中东地区
  • 中南美地区
    • 巴西
    • 阿根廷
    • 其他的中南美地区

第9章 COVID-19疫情对全球胰岛素市场带来的影响

  • 北美
  • 欧洲
  • 亚太地区
  • 中东及非洲
  • 中南美

第10章 胰岛素市场-产业形势

  • 胰岛素市场成长策略(%)
  • 有机开发
  • 无机发展

第11章 企业简介

  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Biocon
  • WOCKHARDT
  • Adocia
  • GlaxoSmithKline plc.
  • Sanofi
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • BIGFOOT BIOMEDICAL, INC.

第12章 附录

  • The Insight Partners
  • 用语说明
Product Code: TIPRE00004051

The insulin market is projected to grow from US$ 54,611.42 million in 2021 to US$ 111,213.73 million by 2028. It is expected to grow at a CAGR of 10.8 % from 2022 to 2028.

The increase in the incidence of diabetes and rapid technological developments in insulin delivery devices by major players is expected to bolster the insulin market in the years to come. Additionally, the regeneration of the diabetic pancreas with advanced transplants is likely to emerge as a significant future trend in the insulin market from 2022 to 2028. However, the risks associated with insulin delivery devices hamper the overall market growth.

In diabetic people, the pancreas does not produce enough insulin, or the body does not usually respond to the insulin, increasing the blood glucose level. Insulin is a hormone that helps in lowering blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and released into the blood when glucose levels rise, for example, after eating. Insulin helps glucose get into the body cells, which can be used for energy or stored for future use. Different types of insulin available vary in how quickly and for how long they can control blood sugar. Insulin does not come in pill form as the digestive system would break it down before it could work. Insulin therapy is exhausting; however, it is an effective way of lowering blood sugar levels.

Products with advanced insulin technology with more benefits are a major requirement in treating diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing worldwide, the demand for advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.

A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:

In May 2022, Eli Lilly and Company received US FDA approval for its Mounjar (tirzepatide) once-weekly Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 Glucagon-like Peptide-1 (GLP-1) receptor agonist for the treatment of adults with type 2 diabetes. The injection is decided to be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as an auto-injector pen with a preattached hidden needle.

In April 2022, Abbott partnered with CamDiab and Ypsomed to develop and commercialize an integrated automated insulin delivery (AID) system for around-the-clock diabetes management.

In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial in China.

In May 2021, Bigfoot Biomedical received 510(k) clearance by the US FDA for its Bigfoot Unity Diabetes Management System, which features connected smartpen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.

Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the global insulin market.

The insulin market is bifurcated into type and geography. Based on type, the global insulin market is segmented into long-acting insulin, short-acting insulin & traditional human insulin, biosimilar insulin, pen & needle, rapid-acting insulin, concentrated insulin & combination insulin, glucagon-like-peptide-1 (GLP-1), pen & needle, and others. The long-acting insulin segment is estimated to account for the largest share during 2022-2028. Longer-acting insulin analogs are genetically engineered. Long-acting insulin analogs were initially developed to address the need of diabetics to maintain healthy blood sugar levels throughout the night. This insulin is slowly released into the circulation due to its acidic pH, causing it to precipitate when injected subcutaneously. Long-acting insulins are also called basal or background insulins. These long-acting insulins help in controlling blood sugar for a whole day. This is similar to how the pancreas produces insulin to maintain blood sugar levels between meals.

Opportunities in Insulin Market

The dominance of major players in developed countries, such as the US, has led to an increase in the global insulin market value. Novo Nordisk A/S, Elli Lily and Company, and Sanofi have a cumulative market revenue of over 90%. This is majorly credited to the evergreening of patents currently held by these dominating players. Additionally, the rising price of insulin in the US is estimated to boost the insulin market further. According to the Centers for Disease Control and Prevention, US$ 1 out of every US$ 4 in US health care costs is expended on diabetic patients.

Moreover, patients' lack of trust in biosimilar drugs is significantly propelling the insulin market. The shortage of biosimilar competition in the market-dominating region of North America is also expected to fuel the market growth. According to a study conducted by Health Action International (2019), Eli Lilly and Company, Novo Nordisk, and Sanofi are the only three manufacturers of insulin in the US, and they generate around 90% of revenue in the global market. In contrast, there are more than eight insulin manufacturers in Asia Pacific, according to the above study.

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Occupational Safety and Health Administration (OSHA), Food and Drug Administration (FDA), Centers for Personalized Medicine (CPM), and Organizations for Economic Co-operation and Development (OECD) are among the primary and secondary sources referred to while preparing the report on the insulin market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the insulin market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global insulin market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. 
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Insulin Market - By Type
    • 1.3.2 Global Insulin Market - By Geography

2. Insulin Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Insulin Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America- PEST Analysis
    • 4.2.2 Europe- PEST Analysis
    • 4.2.3 Asia Pacific- PEST Analysis
    • 4.2.4 Middle East & Africa- PEST Analysis
    • 4.2.5 South & Central America- PEST Analysis
    • 4.2.6 Expert Opinion

5. Insulin Market- Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Incidence of Diabetes
    • 5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
  • 5.2 Market Restraints
    • 5.2.1 Risks Associated with Insulin Delivery Devices
  • 5.3 Market Opportunities
    • 5.3.1 Insufficient Competition from Biosimilars
  • 5.4 Future Trends
    • 5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
  • 5.5 Impact Analysis

6. Insulin Market- Global Analysis

  • 6.1 Global Insulin Market Revenue Forecast and Analysis
    • 6.1.1 Global Insulin Market, By Geography - Forecast and Analysis
    • 6.1.2 Global Insulin Market - Market Potential Analysis, By Region
  • 6.2 Company Analysis
    • 6.2.1 Market Positioning of Key Players
    • 6.2.2 Comparative Company Analysis
    • 6.2.3 Growth Strategy Analysis
    • 6.2.4 Performance Of Key Players
      • 6.2.4.1 Novo Nordisk A/S
      • 6.2.4.2 Sanofi
      • 6.2.4.3 Eli Lily and Company
  • 6.3 Customization Part
    • 6.3.1 Market Share Analysis by Company
    • 6.3.2 Market Share by Injectable GLPs

7. Insulin Market Analysis - By Type

  • 7.1 Overview
  • 7.2 Insulin Market Revenue Share, by Type (2021 and 2028)
  • 7.3 Long Acting Insulin
    • 7.3.1 Overview
    • 7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.3.2.1 Levemir
        • 7.3.2.1.1 Overview
        • 7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.3.2.2 Lantus
        • 7.3.2.2.1 Overview
        • 7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.3.2.3 Basaglar
        • 7.3.2.3.1 Overview
        • 7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.3.2.4 Tresiba
        • 7.3.2.4.1 Overview
        • 7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Rapid Acting Insulins
    • 7.4.1 Overview
    • 7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.1 Novolog
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.2 Humalog
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.3 Admelog
        • 7.4.2.3.1 Overview
        • 7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.4 Others
        • 7.4.2.4.1 Overview
        • 7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Short Acting Insulins and Traditional Human Insulins
    • 7.5.1 Overview
    • 7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.1 Novolin R
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.2 Humulin R
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.3 Insuman
        • 7.5.2.3.1 Overview
        • 7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.4 Others
        • 7.5.2.4.1 Overview
        • 7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Concentrated Insulins and Combination Insulins
    • 7.6.1 Overview
    • 7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.1 NovoMix
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.2 Ryzodeg
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.3 Xultophy
        • 7.6.2.3.1 Overview
        • 7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.4 Soliqua/Suliqua
        • 7.6.2.4.1 Overview
        • 7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Biosimilar Insulins
    • 7.7.1 Overview
    • 7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.1 Insulin Glargine
        • 7.7.2.1.1 Overview
        • 7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.2 Human Insulin
        • 7.7.2.2.1 Overview
        • 7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.8 Glucagon-like peptide-1 (GLP-1)
    • 7.8.1 Overview
    • 7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.9 Pens and Needles
    • 7.9.1 Overview
    • 7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Insulin Market - Geographic Analysis

  • 8.1 North America: Insulin Market
    • 8.1.1 Overview
    • 8.1.2 North America: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    • 8.1.3 North America: Insulin Market, By Type, 2019-2028 (US$ Million)
      • 8.1.3.1 North America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
      • 8.1.3.2 North America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
      • 8.1.3.3 North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
      • 8.1.3.4 North America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
      • 8.1.3.5 North America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
    • 8.1.4 North America: Insulin Market, by Country, 2021 & 2028 (%)
      • 8.1.4.1 US: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
        • 8.1.4.1.1 US: Insulin market - Revenue and Forecast to 2028 (US$ Million)
        • 8.1.4.1.2 US: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.1.4.1.2.1 US: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.1.4.1.2.2 US: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.1.4.1.2.3 US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.1.4.1.2.4 US: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.1.4.1.2.5 US: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.1.4.2 Canada: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
        • 8.1.4.2.1 Canada: Insulin market - Revenue and Forecast to 2028 (US$ Million)
        • 8.1.4.2.2 Canada: Insulin Market , By Type, 2019-2028 (US$ Million)
        • 8.1.4.2.2.1 Canada: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.1.4.2.2.2 Canada: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.1.4.2.2.3 Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.1.4.2.2.4 Canada: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.1.4.2.2.5 Canada: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.1.4.3 Mexico: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
        • 8.1.4.3.1 Mexico: Insulin market - Revenue and Forecast to 2028 (US$ Million)
        • 8.1.4.3.2 Mexico: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.1.4.3.2.1 Mexico: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.1.4.3.2.2 Mexico: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.1.4.3.2.3 Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.1.4.3.2.4 Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.1.4.3.2.5 Mexico: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  • 8.2 Europe: Insulin Market
    • 8.2.1 Overview
    • 8.2.2 Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.3 Europe: Insulin Market, By Type, 2019-2028 (US$ Million)
      • 8.2.3.1 Europe: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
      • 8.2.3.2 Europe: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
      • 8.2.3.3 Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
      • 8.2.3.4 Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
      • 8.2.3.5 Europe: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
    • 8.2.4 Europe: Insulin Market, by Country, 2021 & 2028 (%)
      • 8.2.4.1 Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.1.1 Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.1.2 Germany: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.2.4.1.2.1 Germany: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.1.2.2 Germany: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.1.2.3 Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.2.4.1.2.4 Germany: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.2.4.1.2.5 Germany: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.2.4.2 France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.2.1 France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.2.2 France : Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.2.4.2.2.1 France : Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.2.2.2 France : Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.2.2.3 France : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.2.4.2.2.4 France : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.2.4.2.2.5 France : Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.2.4.3 UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.3.1 UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.3.2 UK: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.2.4.3.2.1 UK: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.3.2.2 UK: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.3.2.3 UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.2.4.3.2.4 UK: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.2.4.3.2.5 UK: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.2.4.4 Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.4.1 Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.4.2 Italy: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.2.4.4.2.1 Italy: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.4.2.2 Italy: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.4.2.3 Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.2.4.4.2.4 Italy: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.2.4.4.2.5 Italy: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.2.4.5 Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.5.1 Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.5.2 Spain: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.2.4.5.2.1 Spain: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.5.2.2 Spain: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.5.2.3 Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.2.4.5.2.4 Spain: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.2.4.5.2.5 Spain: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.2.4.6 Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.6.1 Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.2.4.6.2 Rest of Europe: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.2.4.6.2.1 Rest of Europe: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.6.2.2 Rest of Europe: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.2.4.6.2.3 Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.2.4.6.2.4 Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.2.4.6.2.5 Rest of Europe: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  • 8.3 Asia Pacific: Insulin Market
    • 8.3.1 Overview
    • 8.3.2 Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.3.3 Asia Pacific: Insulin Market, by Type, 2019-2028 (US$ Million)
      • 8.3.3.1 Asia Pacific: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
      • 8.3.3.2 Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
      • 8.3.3.3 Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
      • 8.3.3.4 Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
      • 8.3.3.5 Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
    • 8.3.4 Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
      • 8.3.4.1 China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.1.1 China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.1.2 China: Insulin Market, by Type, 2019-2028 (US$ Million)
        • 8.3.4.1.2.1 China: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.3.4.1.2.2 China: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
        • 8.3.4.1.2.3 China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.3.4.1.2.4 China: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.3.4.1.2.5 China: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.3.4.2 Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.2.1 Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.2.2 Japan: Insulin Market, by Type, 2019-2028 (US$ Million)
        • 8.3.4.2.2.1 Japan: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.3.4.2.2.2 Japan: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
        • 8.3.4.2.2.3 Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.3.4.2.2.4 Japan: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.3.4.2.2.5 Japan: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.3.4.3 India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.3.1 India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.3.2 India: Insulin Market, by Type, 2019-2028 (US$ Million)
        • 8.3.4.3.2.1 India: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.3.4.3.2.2 India: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
        • 8.3.4.3.2.3 India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.3.4.3.2.4 India: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.3.4.3.2.5 India: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.3.4.4 Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.4.1 Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.4.2 Australia: Insulin Market, by Type, 2019-2028 (US$ Million)
        • 8.3.4.4.2.1 Australia: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.3.4.4.2.2 Australia: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
        • 8.3.4.4.2.3 Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.3.4.4.2.4 Australia: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.3.4.4.2.5 Australia: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.3.4.5 South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.5.1 South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.5.2 South Korea: Insulin Market, by Type, 2019-2028 (US$ Million)
        • 8.3.4.5.2.1 South Korea: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.3.4.5.2.2 South Korea: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
        • 8.3.4.5.2.3 South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.3.4.5.2.4 South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.3.4.5.2.5 South Korea: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.3.4.6 Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.6.1 Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
        • 8.3.4.6.2 Rest of Asia Pacific: Insulin Market, by Type, 2019-2028 (US$ Million)
        • 8.3.4.6.2.1 Rest of Asia Pacific: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.3.4.6.2.2 Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
        • 8.3.4.6.2.3 Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.3.4.6.2.4 Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.3.4.6.2.5 Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  • 8.4 Middle East & Africa Insulin Market Revenue and Forecasts To 2028
    • 8.4.1 Overview
    • 8.4.2 Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
    • 8.4.3 Middle East & Africa : Insulin Market, By Type, 2019-2028 (US$ Million)
      • 8.4.3.1 Middle East & Africa : Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
      • 8.4.3.2 Middle East & Africa : Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
      • 8.4.3.3 Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
      • 8.4.3.4 Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
      • 8.4.3.5 Middle East & Africa : Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
    • 8.4.4 Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
      • 8.4.4.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.1.2 UAE: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.4.4.1.2.1 UAE: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.1.2.2 UAE: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.1.2.3 UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.4.4.1.2.4 UAE: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.4.4.1.2.5 UAE: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.4.4.2 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.2.1 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.2.2 Saudi Arabia: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.4.4.2.2.1 Saudi Arabia: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.2.2.2 Saudi Arabia: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.2.2.3 Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.4.4.2.2.4 Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.4.4.2.2.5 Saudi Arabia: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.4.4.3 South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.3.1 South Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.3.2 South Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.4.4.3.2.1 South Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.3.2.2 South Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.3.2.3 South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.4.4.3.2.4 South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.4.4.3.2.5 South Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.4.4.4 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.4.1 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
        • 8.4.4.4.2 Rest of Middle East & Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.4.4.4.2.1 Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.4.2.2 Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.4.4.4.2.3 Rest of Middle East & Africa: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.4.4.4.2.4 Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.4.4.4.2.5 Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  • 8.5 South and Central America Insulin Market Revenue and Forecasts To 2028
    • 8.5.1 Overview
    • 8.5.2 South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    • 8.5.3 South and Central America: Insulin Market, By Type, 2019-2028 (US$ Million)
      • 8.5.3.1 South and Central America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
      • 8.5.3.2 South and Central America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
      • 8.5.3.3 South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
      • 8.5.3.4 South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
      • 8.5.3.5 South and Central America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
    • 8.5.4 South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
      • 8.5.4.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
        • 8.5.4.1.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
        • 8.5.4.1.2 Brazil: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.5.4.1.2.1 Brazil: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.5.4.1.2.2 Brazil: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.5.4.1.2.3 Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.5.4.1.2.4 Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.5.4.1.2.5 Brazil: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.5.4.2 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
        • 8.5.4.2.1 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
        • 8.5.4.2.2 Argentina: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.5.4.2.2.1 Argentina: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.5.4.2.2.2 Argentina: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.5.4.2.2.3 Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.5.4.2.2.4 Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.5.4.2.2.5 Argentina: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
      • 8.5.4.3 Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
        • 8.5.4.3.1 Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
        • 8.5.4.3.2 Rest of South and Central America: Insulin Market, By Type, 2019-2028 (US$ Million)
        • 8.5.4.3.2.1 Rest of South and Central America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
        • 8.5.4.3.2.2 Rest of South and Central America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
        • 8.5.4.3.2.3 Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
        • 8.5.4.3.2.4 Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
        • 8.5.4.3.2.5 Rest of South and Central America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)

9. Impact of COVID-19 Pandemic on Global Insulin Market

  • 9.1 North America: Impact Assessment of COVID-19 Pandemic
  • 9.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 9.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
  • 9.5 South and Central America: Impact Assessment of COVID-19 Pandemic

10. Insulin Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Insulin Market (%)
  • 10.3 Organic Developments
    • 10.3.1 Overview
  • 10.4 Inorganic Developments
    • 10.4.1 Overview

11. Company Profile

  • 11.1 Eli Lilly and Company
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Novo Nordisk A/S
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Biocon
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 WOCKHARDT
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Adocia
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 GlaxoSmithKline plc.
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Sanofi
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Pfizer Inc.
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Merck & Co., Inc.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments
  • 11.11 BIGFOOT BIOMEDICAL, INC.
    • 11.11.1 Key Facts
    • 11.11.2 Business Description
    • 11.11.3 Products and Services
    • 11.11.4 Financial Overview
    • 11.11.5 SWOT Analysis
    • 11.11.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. North America: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. North America: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 3. North America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. North America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 6. North America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 7. US: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. US: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 9. US: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million) 97
  • Table 11. US: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 12. US: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Canada: Insulin Market , By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Canada: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 15. Canada: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Canada: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Canada: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Mexico: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Mexico: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 21. Mexico: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Mexico: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Europe: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Europe: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 27. Europe: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 30. Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 31. Germany: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. Germany: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 33. Germany: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 34. Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 35. Germany: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 36. Germany: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 37. France: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 38. France : Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 39. France : Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 40. France : Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 41. France : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 42. France : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 43. UK: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 44. UK: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 45. UK: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 46. UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 47. UK: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 48. UK: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 49. Italy: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 50. Italy: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 51. Italy: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 52. Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 53. Italy: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 54. Italy: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 55. Spain: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 56. Spain: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 57. Spain: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 58. Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 59. Spain: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 60. Spain: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 61. Rest of Europe: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 62. Rest of Europe: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 63. Rest of Europe: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 64. Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 65. Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 66. Rest of Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 67. Asia Pacific: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 68. Asia Pacific: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 69. Asia Pacific: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 70. Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 71. Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 72. Asia Pacific: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 73. China: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 74. China: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 75. China: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 76. China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 77. China: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 78. China: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 79. Japan: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 80. Japan: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 81. Japan: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 82. Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 83. Japan: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 84. Japan: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 85. India: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 86. India: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 87. India: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 88. India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 89. India: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 90. India: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 91. Australia: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 92. Australia: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 93. Australia: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 94. Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 95. Australia: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 96. Australia: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 97. South Korea: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 98. South Korea: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 99. South Korea: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 100. South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 101. South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 102. South Korea: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 103. Rest of Asia Pacific: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 104. Rest of Asia Pacific: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 105. Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 106. Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 107. Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 108. Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 109. Middle East & Africa : Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 110. Middle East & Africa : Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 111. Middle East & Africa : Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 112. Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 113. Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 114. Middle East & Africa : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 115. UAE: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 116. UAE: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 117. UAE: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 118. UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 119. UAE: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 120. UAE: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 121. Saudi Arabia: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 122. Saudi Arabia: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 123. Saudi Arabia: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 124. Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 125. Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 126. Saudi Arabia: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 127. South Africa: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 128. South Africa: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 129. South Africa: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 130. South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 131. South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 132. South Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 133. Rest of Middle East & Africa: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 134. Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 135. Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 136. Rest of Middle East & Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 137. Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 138. Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 139. South and Central America: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 140. South and Central America: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 141. South and Central America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 142. South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 143. South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 144. South and Central America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 145. Brazil: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 146. Brazil: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 147. Brazil: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 148. Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 149. Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 150. Brazil: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 151. Argentina: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 152. Argentina: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 153. Argentina: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 154. Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 155. Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 156. Argentina: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 157. Rest of South and Central America: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 158. Rest of South and Central America: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
  • Table 159. Rest of South and Central America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
  • Table 160. Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
  • Table 161. Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 162. Rest of South and Central America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
  • Table 163. Organic Developments in the Insulin Market
  • Table 164. Inorganic Developments in the Insulin Market
  • Table 165. Glossary of Terms, Insulin Market

List Of Figures

  • Figure 1. Insulin Market Segmentation
  • Figure 2. Insulin Market Segmentation, By Region
  • Figure 3. Global Insulin Market Overview
  • Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
  • Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
  • Figure 6. Global Insulin Market, By Geography (US$ Million)
  • Figure 7. Global Insulin Market- Leading Country Markets (US$ Million)
  • Figure 8. Global Insulin Market, Industry Landscape
  • Figure 9. North America PEST Analysis
  • Figure 10. Europe PEST Analysis
  • Figure 11. Asia Pacific PEST Analysis
  • Figure 12. Middle East & Africa PEST Analysis
  • Figure 13. South & Central America PEST Analysis
  • Figure 14. Expert Opinion
  • TABLE 1. PREVALENCE OF DIABETES WORLDWIDE, 2021
  • Figure 15. Insulin Market Impact Analysis of Drivers and Restraints
  • Figure 16. Global Insulin Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 17. Global Insulin Market - By Geography Forecast and Analysis - 2021 - 2028
  • Figure 18. Global Insulin Market - Market Potential Analysis, By Region
  • Figure 19. Market Positioning of Key Players In Global Insulin Market
  • Figure 20. Global Insulin Market - Comparative Company Analysis
  • Figure 21. Global Insulin Market - Growth Strategy Analysis
  • Figure 22. Insulin Market Revenue Share, by Type (2021 and 2028)
  • Figure 23. Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 42. Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. North America Insulin Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 50. North America Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 51. North America: Insulin Market, by Country, 2021 & 2028 (%)
  • Figure 52. US: Insulin market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. Canada: Insulin market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 54. Mexico: Insulin market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. Europe: Insulin Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 56. Europe Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Europe: Insulin Market, by Country, 2021 & 2028 (%)
  • Figure 58. Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 59. France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 61. Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 63. Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 64. Asia Pacific: Insulin Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 65. Asia Pacific: Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 66. Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
  • Figure 67. China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 68. Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 69. India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 70. Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 71. South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 72. Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 73. Middle East & Africa Insulin Market Revenue Overview, by Country, 2021 (US$ Million)
  • Figure 74. Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 75. Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
  • Figure 76. UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 77. Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 78. South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 79. Rest of Middle East & Africa: Insulin MarketRevenue and Forecast to 2028 (US$ Million)
  • Figure 80. South and Central America Insulin Market Revenue Overview, By Country (2021) (US$ Mn)
  • Figure 81. South and Central America Insulin Market Revenue and Forecast to 2028 (USD Million)
  • Figure 82. South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
  • Figure 83. Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
  • Figure 84. Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
  • Figure 85. Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
  • Figure 86. Impact Of COVID-19 Pandemic in North American Country Markets
  • Figure 87. Impact Of COVID-19 Pandemic in Europe Country Markets
  • Figure 88. Impact of COVID-19 Pandemic in Asia Pacific Countries
  • Figure 89. Impact Of COVID-19 Pandemic in Middle East & Africa Country Markets
  • Figure 90. Impact of COVID-19 Pandemic in South and Central American Countries
  • Figure 91. Growth Strategies in the Insulin Market (%)